UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan · Delayed Price · Currency is TWD 87.00
+0.10 (0.12%)
Feb 11, 2026, 1:30 PM CST
UnicoCell Biomed Revenue
UnicoCell Biomed had revenue of 5.23M TWD in the quarter ending September 30, 2025, a decrease of -64.35%. This brings the company's revenue in the last twelve months to 34.58M, up 18.92% year-over-year. In the year 2024, UnicoCell Biomed had annual revenue of 31.88M with 29.66% growth.
Revenue (ttm)
34.58M
Revenue Growth
+18.92%
P/S Ratio
152.49
Revenue / Employee
n/a
Employees
27
Market Cap
5.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.88M | 7.29M | 29.66% |
| Dec 31, 2023 | 24.59M | 10.19M | 70.79% |
| Dec 31, 2022 | 14.40M | 6.22M | 76.07% |
| Dec 31, 2021 | 8.18M | 4.20M | 105.35% |
| Dec 31, 2020 | 3.98M | -11.76M | -74.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.35B |
| Panion & Bf Biotech | 2.04B |
| Savior Lifetec | 1.16B |
| BioGend Therapeutics | 212.43M |
| Pharmosa Biopharm | 136.72M |
| OBI Pharma | 49.29M |
| AnnJi Pharmaceutical | 23.85M |
| Locus Cell | 5.18M |